Development and Validation of a Simplified Prognostic Score in SCLC

Autor: Elodie Negre, MD, Amandine Coffy, BSc, Alexandra Langlais, BSc, Jean-Pierre Daures, MD, PhD, Armelle Lavole, MD, Elisabeth Quoix, MD, PhD, Olivier Molinier, MD, Laurent Greillier, MD, PhD, Clarisse Audigier-Valette, MD, Denis Moro-Sibilot, MD, PhD, Virginie Westeel, MD, PhD, Franck Morin, PhD, Benoît Roch, MD, Jean-Louis Pujol, MD, PhD

Publikováno v: JTO Clinical and Research Reports, Vol 1, Iss 1, Pp 100016- (2020)

Introduction: This study aimed at generating a new simplified prognostic score (SPS) using common clinical and biological variables to discriminate a limited number of subgroups of patients with SCLC differing by their overall survival (OS). Methods:

Externí odkaz: https://doaj.org/article/1cc090aaaba44673962212a5da2c6435

Predominance of

Autor: Pascal, Pujol, Kevin, Yauy, Amandine, Coffy, Nicolas, Duforet-Frebourg, Sana, Gabteni, Jean-Pierre, Daurès, Frédérique, Penault Llorca, Frédéric, Thomas, Kevin, Hughes, Clare, Turnbull, Virginie, Galibert, Chloé, Rideau, Carole, Corsini, Laetitia, Collet, Benoit, You, David, Geneviève, Nicolas, Philippe

Publikováno v: Cancers. 14(13)

Poly(ADP-ribose) polymerase 1 inhibitor (PARPi) agents can improve progression-free survival of patients with breast cancer who carry a germline BRCA1 or BRCA2 pathogenic or likely pathogenic variant (gBRCA) in both the metastatic and adjuvant settin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::927af34228552b4a6a30f7ac3f831afe
https://pubmed.ncbi.nlm.nih.gov/35805038

Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors

Autor: Sandy Jean-Baptiste, Amandine Coffy, Jean-Pierre Daurès, Jean-Louis Pujol, Sébastien Bommart, Benoît Roch, Estelle Palaysi

Publikováno v: Lung Cancer
Lung Cancer, Elsevier, 2020, 143, pp.19-26. ⟨10.1016/j.lungcan.2020.03.003⟩
Lung Cancer, 2020, 143, pp.19-26. ⟨10.1016/j.lungcan.2020.03.003⟩

International audience; Purpose: The metabolic changes associated with cachexia – sarcopenia syndrome might down-regulate antitumor immunity. We hypothesized that this syndrome reduces efficiency of immune checkpoint inhibitors (ICPI) in non-small

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a16d07b8b27b3cb69f94e5ddc476762
https://doi.org/10.1016/j.lungcan.2020.03.003

French cross-cultural adaptation and validity of the Moorong Self-Efficacy scale: the MSES-FR, a measure of Self-Efficacy for French people with spinal cord injury

Autor: Jacques Kerdraon, Hubert Tournebise, James W. Middleton, Dominique Gault, A. Gelis, Marion Gounelle, Violaine Leynaert, Benoit Nicolas, Florence Cousson-Gélie, Amandine Coffy, David Goossens

Publikováno v: Disability and rehabilitation. 44(25)

Purpose To adapt the Moorong Self-Efficacy Scale (MSES) in the French language and determine its psychometric proprieties. Materials and methods After a back-translation process, an expert committee was solicited to develop the French Self Efficacy S

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbc287e65dd9fe28434e8c8099c672a9
https://pubmed.ncbi.nlm.nih.gov/34802337

Predominance of BRCA2 mutation and estrogen receptor-positive breast cancer among BRCA1/2 mutation carriers

Autor: Pascal Pujol, Kévin Yauy, Amandine Coffy, Nicolas Duforet-Frebourg, Sana Gabteni, Jean-Pierre Daurès, Frédérique Penault-Llorca, Frédéric Thomas, Kevin Hughes, Clare Turnbull, Virginie Galibert, Chloé Rideau, Laetitia Collet, Benoit You, David Geneviève, Nicolas Philippe

Publikováno v: Journal of Clinical Oncology. 40:551-551

Background: PARP inhibitor (PARPi) agents can improve progression-free survival of patients with breast cancer (BC) who carry a germline BRCA1 or BRCA2 pathogenic or likely pathogenic variant (gBRCA1/2) in both the metastatic and adjuvant setting. Th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::717527490d66e879bf61ee820bb837bd
https://doi.org/10.1200/jco.2022.40.16_suppl.551